Co-trimoxazole for idiopathic pulmonary fibrosis: time for TIPAC-2?

The authors discuss the results of TIPAC, a randomised placebo controlled trial of co-trimoxazole in patients with idiopathic pulmonary fibrosis (IPF). They mention that so far there is only one drug pirfenidone that has been approved for use in Europe and that may slow the progression of the disease. The results cleared that co-trimoxazole treatment may reduce all-cause mortality and improve overall health-related quality of life.